Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Bristol-Myers Squibb Compa
Bristol-Myers Squibb Company specializes in the development, manufacturing and marketing of pharmaceutical products. Products are intended for the treatment of cancers, cardiovascular diseases, hepatitis, immune diseases and psychiatric disorders.

Net sales are distributed geographically as follows: the United States (58.7%), Europe (24%) and other (17.3%).

Number of employees : 30 000 people.
Sales per Business
20182019Delta
USD (in Million)%USD (in Million)%
Net Product21,58195.7%25,17496.3% +16.65%
Alliance647.002.9%597.002.3% -7.73%
Other333.001.5%374.001.4% +12.31%
Sales per region
20182019Delta
USD (in Million)%USD (in Million)%
United States12,58655.8%15,34258.7% +21.9%
Europe5,65825.1%6,26624% +10.75%
Rest of the World3,73316.5%4,01315.3% +7.5%
Other584.002.6%524.002% -10.27%
Managers
NameAgeSinceTitle
Giovanni Caforio542017Chairman & Chief Executive Officer
David V. Elkins502019Chief Financial Officer & Executive Vice President
Paul von Autenried572008Chief Information Officer & Senior Vice President
Vicki L. Sato, Dr.702006Lead Independent Director
Gerald L. Storch622012Independent Director
Dinesh C Paliwal612013Independent Director
Peter Arduini542016Independent Director
Robert J. Bertolini572017Independent Director
Matthew Emmens672017Independent Director
Theodore Rapp Samuels642017Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 2,922,689,755 2,260,659,374 77.3% 660,000,000 22.6% 77.3%
Shareholders
NameEquities%
Capital Research & Management Co. 203,897,400 9.01%
The Vanguard Group, Inc. 187,208,149 8.27%
SSgA Funds Management, Inc. 100,852,572 4.46%
Wellington Management Co. LLP 75,508,261 3.34%
Renaissance Technologies LLC 65,992,111 2.92%
BlackRock Fund Advisors 57,012,282 2.52%
Fidelity Management & Research Co. 56,550,899 2.50%
Geode Capital Management LLC 40,234,001 1.78%
JPMorgan Investment Management, Inc. 38,172,580 1.69%
Dodge & Cox 36,277,074 1.60%
Holdings
NameEquities%Valuation
Acceleron Pharma Inc. (XLRN) 6,824,68512.8%617,838,733 USD
Agios Pharmaceuticals, Inc. (AGIO) 7,121,65810.4%292,985,010 USD
uniQure N.V. (QURE) 2,388,1085.59%151,979,193 USD
Epizyme, Inc. (EPZM) 3,674,6403.64%60,484,574 USD
Zymeworks Inc. (ZYME) 1,539,4833.38%56,237,314 USD
Sutro Biopharma, Inc. (STRO) 1,726,1977.43%17,003,040 USD
Jounce Therapeutics, Inc. (JNCE) 3,456,46310.2%16,936,669 USD
IDEAYA Biosciences, Inc. (IDYA) 1,633,2538.01%9,064,554 USD
Markets and indexes
- NYSE
- Main Market
- SP 100 / SP 500, Stoxx Americas 100, Stoxx Global 200
Stock Exchange Codes
- Bloomberg Code :  BMY:US
- Reuters Code :  BMY.N
- Datastream Code :  
Company contact information
Bristol-Myers Squibb Company
14th Floor 430 E Street 29th
NY 10016 New York City, New York
États-Unis (les)

Phone : +1 212 546 4000
Fax : +1
Internet : https://www.bms.com/investors.html
Brand Portfolio
In partnership withAllbrands.markets
More brands of Bristol-Myers Squibb Company
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-6.96%135 128
JOHNSON & JOHNSON1.97%391 896
ROCHE HOLDING AG5.96%295 228
PFIZER, INC.-2.53%212 139
MERCK & CO., INC.-11.25%203 745
NOVARTIS AG-9.65%190 274
ABBVIE INC.4.66%163 316
NOVO NORDISK A/S12.83%152 054
ASTRAZENECA PLC14.13%138 964
ELI LILLY AND COMPANY16.37%138 642
AMGEN INC.-4.72%135 120
SANOFI SA-2.33%121 900
GLAXOSMITHKLINE PLC-7.11%102 688
CHUGAI PHARMACEUTICAL CO., LTD.57.64%80 786
BAYER AG-16.60%66 318
ALLERGAN PLC0.97%63 659
DAIICHI SANKYO COMPANY, LIMITED39.53%60 685
TAKEDA PHARMACEUTICAL COMPANY LIMITED-3.25%60 618
JIANGSU HENGRUI MEDICINE CO., LTD.7.91%58 278
ASTELLAS PHARMA INC.2.38%33 035
HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED29.92%25 693